Treatment Clinical Trial
Official title:
Androgen Deprivation Therapy (ADT) Versus Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer: A Prospective Randomized Control Clinical Trial
The aim of this study is to test the safety and feasibility of SBRT without ADT in oligometastatic prostate cancer in patients for whom the standard treatment is ADT, and to further explore how long only radiotherapy for oligometastases can prolong biochemical progression-free survival (bPFS). In this study, men with oligometastatic prostate cancer lesions will be randomized (1:1) to ADT versus SBRT. Within 6 weeks of the oligometastases diagnosis, ADT or SBRT (30-50Gy with 3-5 fractions) will be administered.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | October 1, 2025 |
Est. primary completion date | November 11, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - 80 years old - Histologically confirmed adenocarcinoma of the prostate - Prostate cancer treated with curative intent (radical prostatectomy, primary radiotherapy, or a combination of both) - Ga-68 prostate-specific membrane antigen (PSMA) PET/CT evidence of one to three metastases (bone or lymph node) within 6 weeks of enrolment, if the position of oligometastases is judged by the doctor to be in the same radiotherapy area, the number of metastases can be appropriately increased to 5 - Without ADT treatment - PSA< 50ng/ml - ECOG performance status 0-2 - Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures Exclusion Criteria: - Any previous or ongoing treatment of oligometastases including radiotherapy, ADT, chemotherapy, focal treatment, etc. - Unstable lesions with spinal or long bone metastases - A tumor located at less than 3 mm from the urethra or rectum when measured at the MRI - 4 metastases, or if the metastases are in the same radiotherapy area, =6 metastases - Histologically confirmed neuroendocrine tumor or small cell carcinoma of the prostate - Severe or active co-morbidity likely to impact on the advisability of SBRT like severe liver or kidney dysfunction, etc. - Patients with other malignancies, or acute or other severe infections, with ulcerative colitis, inflammatory bowel disease, etc. - Patients who have participated in other clinical trials for less than three months - Unsuitable to participate in this clinical trial judged by the investigator |
Country | Name | City | State |
---|---|---|---|
China | Changhai hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Changhai Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1-year ADT-free survival of the experimental group | To assess ADT-free survival of the experimental group | Assessment ADT-free survival of the experimental group at 1 year | |
Primary | The Probability of Radiotherapy-related Toxicity | Radiotherapy-related complications | Assessment Toxicity at 1 year | |
Primary | The time from inception of the study to castration-resistant prostate cancer (CRPC) | the time from inception of the study to castration-resistant prostate cancer (CRPC) | Assessment at 1 year | |
Secondary | 1-year Efficacy Biochemical Progression-free Survival (bPFS) | Biochemical Progression-free Survival (bPFS) | 1 year | |
Secondary | 1-year Local Progression-Free-Survival(LPFS) | Local Progression-Free-Survival(LPFS) | Assessment at 1 year | |
Secondary | 1-year Distant Metastasis Free Survival(DMFS) | Distant Metastasis Free Survival(DMFS) | Assessment at 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05243134 -
The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
|
||
Completed |
NCT02486874 -
Clinical Evaluation of PoreSkin
|
Phase 1 | |
Active, not recruiting |
NCT04592640 -
Stem Cells for Uremic Calciphylaxis Patients
|
N/A | |
Recruiting |
NCT03351842 -
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
|
Phase 2 | |
Completed |
NCT02782442 -
Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)
|
N/A | |
Completed |
NCT03439930 -
The Effect of Balance Training on Neuromuscular Control in Subjects With CAI
|
N/A | |
Not yet recruiting |
NCT05537155 -
Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery
|
N/A | |
Recruiting |
NCT02971982 -
PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
|
Phase 1/Phase 2 | |
Completed |
NCT02820272 -
Water for Reducing Pain in Negative Pressure Wound Therapy
|
Phase 2 | |
Completed |
NCT00984958 -
Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure
|
N/A | |
Completed |
NCT00575224 -
Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9
|
Phase 4 | |
Completed |
NCT00164307 -
Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships
|
Phase 1/Phase 2 | |
Completed |
NCT00164528 -
Intervening With Children/Adolescents With FAS/ARND
|
Phase 1/Phase 2 | |
Recruiting |
NCT04603586 -
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
|
N/A | |
Recruiting |
NCT03375424 -
Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany
|
N/A | |
Not yet recruiting |
NCT04062370 -
Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 4 | |
Not yet recruiting |
NCT02931136 -
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
|
Phase 4 | |
Completed |
NCT04661228 -
Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
|
||
Recruiting |
NCT03365141 -
Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo
|
N/A | |
Recruiting |
NCT04599699 -
Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 PSMA PET/MR Study of SBRT With Prostate Cancer
|
N/A |